Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Diamedica Therapeutics Inc (DMAC)

Diamedica Therapeutics Inc (DMAC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
MarketBeat.com
DiaMedica Therapeutics Q1 Earnings Call Highlights MarketBeat - Thu May 7, 12:42PM CDT

DiaMedica Therapeutics (NASDAQ:DMAC) executives outlined progress across the company’s DM199 clinical programs in preeclampsia and acute ischemic stroke during the company’s first-quarter 2026 earnings...

DMAC : 6.45 (+2.06%)
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights Business Wire - Wed May 6, 3:30PM CDT

DM199 Preeclampsia Phase 2 Investigator-Sponsored Trial (IST) Part 1a Expansion Cohort Enrolling, Updated Dataset Expected 2Q 2026 ...

DMAC : 6.45 (+2.06%)
DMAC's Preeclampsia Bet May Already Be Priced Into Eighteen-Cent Loss Estimate Barchart - Tue May 5, 4:09PM CDT

Barchart Research What to Expect from DMAC Earnings DMAC Generated May 5, 2026 Current Price $6.24 EPS Estimate $$-0.17 Consensus Rating Strong Buy Average Move 7.15% DMAC's Preeclampsia Bet May Already...

DMAC : 6.45 (+2.06%)
DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026 Business Wire - Thu Apr 30, 7:25AM CDT

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS),...

DMAC : 6.45 (+2.06%)
RedChip's Biotech Virtual Investor Conference Replays Now Available ACCESS Newswire - Tue Apr 21, 10:00AM CDT

ORLANDO, FL / ACCESS Newswire / April 21, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced that on-demand replays...

CLDI : 0.1985 (-5.70%)
INAB : 1.6250 (+2.85%)
DMAC : 6.45 (+2.06%)
NSRX : 3.04 (-3.49%)
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms ACCESS Newswire - Tue Apr 7, 6:00AM CDT

ORLANDO, FL / ACCESS Newswire / April 7, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming virtual...

CLDI : 0.1985 (-5.70%)
INAB : 1.6250 (+2.85%)
CNTB : 2.34 (-0.85%)
DMAC : 6.45 (+2.06%)
NSRX : 3.04 (-3.49%)
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights Business Wire - Mon Mar 30, 3:45PM CDT

Received Regulatory Approval from Health Canada Supporting Initiation of Phase 2 DM199 Study in Early-onset Preeclampsia. DM199...

DMAC : 6.45 (+2.06%)
Diamedica Has Been Quietly Running Its Trials. Monday, the Silence Ends. Barchart - Sun Mar 29, 4:00PM CDT

Barchart Research What to Expect from DMAC Earnings DMAC Generated March 27, 2026 Current Price $6.79 EPS Estimate $-0.17 Consensus Rating Strong Buy Average Move 7.13% Diamedica Has Been Quietly Running...

DMAC : 6.45 (+2.06%)
Diamedica Has Been Quietly Running Its Trials. Monday, the Silence Ends. Barchart - Sat Mar 28, 4:01PM CDT

Barchart Research What to Expect from DMAC Earnings DMAC Generated March 27, 2026 Current Price $6.79 EPS Estimate $-0.17 Consensus Rating Strong Buy Average Move 7.13% Diamedica Has Been Quietly Running...

DMAC : 6.45 (+2.06%)
Diamedica Has Been Quietly Running Its Trials. Monday, the Silence Ends. Barchart - Fri Mar 27, 4:02PM CDT

Barchart Research What to Expect from DMAC Earnings DMAC Generated March 27, 2026 Current Price $6.79 EPS Estimate $-0.17 Consensus Rating Strong Buy Average Move 7.13% Diamedica Has Been Quietly Running...

DMAC : 6.45 (+2.06%)

Barchart Exclusives

Berkshire Hathaway Just Upped Its Stake in Sumitomo Stock. Greg Abel Says It’s Holding for the Long Term. Barchart - Mon May 11, 6:30PM CDT
Berkshire Hathaway has raised its stake in Sumitomo to 10.05% as of May 7, crossing the 10% threshold in all five major Japanese trading houses and signaling a long-term “permanent” holding under CEO Greg Abel. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.